Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

Research output: Contribution to journalReview article

Abstract

Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity. Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.Leukemia advance online publication, 27 February 2015; doi:10.1038/leu.2015.29.

Details

Authors
  • N C P Cross
  • H E White
  • D Colomer
  • L Foroni
  • E Gottardi
  • T Lange
  • T Lion
  • K Machova Polakova
  • S Dulucq
  • G Martinelli
  • E Oppliger Leibundgut
  • N Pallisgaard
  • G Barbany
  • T Sacha
  • R Talmaci
  • B Izzo
  • G Saglio
  • F Pane
  • M C Müller
  • A Hochhaus
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)999-1003
JournalLeukemia
Volume29
Issue number5
Publication statusPublished - 2015
Publication categoryResearch
Peer-reviewedYes

Total downloads

No data available